RESEARCH SPOTLIGHT: Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia
LMC Manna Research’s Chief Medical officer Dr. Ronnie Aronson shares our latest publication showcasing our collaborative work with the medications lixisenatide and LixiLan (lixisenatide & lantus combination) over the past decade. This publication is a...
RESEARCH SPOTLIGHT: Reproducibility in the cardiometabolic responses to high-intensity interval exercise in adults with type 1 diabetes
With one month of 2019 already completed, we are excited to share a 2nd FIT published paper from LMC Manna Research’s very own Scientist Team led by Chief Medical Officer Dr. Ronnie Aronson and Senior Scientist Michael Riddell.This 2nd paper highlights...
LMC Brampton Grand Opening
Join us on February 28, 2018 for the Grand Opening of our new LMC Brampton clinic location!
LMC Diabetes & Endocrinology is now LMC Healthcare
Welcome to LMC Healthcare, our new company name with a fresh, new look! We're Here for You Canada's largest and most trusted specialist care provider in diabetes & endocrinology Dedicated to transforming diabetes care for the better by making it more...
LMC|Manna Research – Winner of 2017 SPRIA Award
On October 6-8th, 2017, LMC?Manna Research's Management Team was represented at the Society of Clinical Research Sites (SCRS) annual Global Solutions Summit Conference in Boca Raton, Florida. Nazneen Qureshi, Manager Patient Engagement, representing LMC | Manna...
LMC|Manna Research – Winner of 2017 Clinical Research Coordinator of the Year – The Americas Award
LMC | Manna Research's own Lydia Frost, Regional Site Lead – Research, won the 2017 Clinical Research Coordinator of the Year - The Americas Award, presented by PharmaTimes Media Ltd. This year’s competition was held in association with the ACRP 2017 Meeting &...
LMC Now Providing Telemedicine Consult Appointments to Patients in the Minto-Mapleton Area
LMC's telemedicine service is dedicated to the provision of medical consultation and follow-up services for Diabetes & Endocrine conditions to individuals over the age of 18 living in the various LHIN’s. We have recently begun accepting referrals from...
Sanofi receives FDA approval of AdlyxinTM for treatment of adults with Type 2 Diabetes
Sanofi announced on July 28th that the U.S. Food and Drug Administration (FDA) approved AdlyxinTM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes. “The...
NEW STUDY IN ONTARIO: DO YOU HAVE TYPE 1 DIABETES? ARE YOUR GLUCOSE LEVELS OFF TARGET?
LMC is looking for individuals with type 1 diabetes to participate in a research study involving an experimental insulin medication that may help lower meal-time glucose levels. Study related medication, supplies, and travel expenses may be provided. Speak with a...
NEW STUDY IN ALBERTA: DO YOU HAVE TYPE 1 DIABETES? ARE YOUR GLUCOSE LEVELS OFF TARGET?
LMC is looking for individuals with type 1 diabetes to participate in a research study involving an experimental insulin medication that may help lower meal-time glucose levels. Study related medication, supplies, and travel expenses may be provided. Speak with a...